The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase1b study of navicixizumab plus FOLFIRI in second-line treatment of patients with metastatic colorectal cancer.
 
Kian-Huat Lim
Honoraria - Jacobio
Research Funding - Aclaris Therapeutics
 
Michael Iglesia
No Relationships to Disclose
 
Kerry Culm
Employment - Oncologie
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Patents, Royalties, Other Intellectual Property - Patent on administration of IMGN632 and IMGN779
 
Andrew G. Koustenis
No Relationships to Disclose
 
Colleen M. Mockbee
Employment - OncXerna Therapeutics
Leadership - OncXerna Therapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics; Krystal Biotech; Mirati Therapeutics; Rocket Pharma; Sarepta Therapeutics
Consulting or Advisory Role - Elevation Oncology; Partner Therapeutics
 
Lynn Mathew
No Relationships to Disclose
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Incyte; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); Verastem (Inst)
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Jazz Pharmaceuticals; Kanaph Therapeutics; OncXerna Therapeutics; SOTIO
Research Funding - Bayer (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Repare Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tolero Pharmaceuticals (Inst)
 
John C. Krauss
Research Funding - Abbvie (Inst); Abbvie (Inst); ACCRU (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Cardiff Oncology; Daiichi Sankyo/Arqule (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Isofol Medical (Inst); Novartis (Inst); NSABP FOUNDATION (Inst); NSABP Foundation (Inst); Pfizer (Inst); Tempest Therapeutics (Inst); Tempest Therapeutics (Inst)